.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
QuintilesIMS
Deloitte
Chinese Patent Office
Merck
Harvard Business School
Baxter
Daiichi Sankyo
Farmers Insurance
AstraZeneca

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,528,545

« Back to Dashboard

Which drugs does patent 8,528,545 protect, and when does it expire?


Patent 8,528,545 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-six countries.

Summary for Patent: 8,528,545

Title:Inhaler device that reduces the risk for miscounting a dosage
Abstract: Inhaler device (10) comprising an actuator body (20) and an inhaler canister assembly (70), the inhaler canister assembly (70) is comprised of a canister (30) with a metering valve at a valve end and a dose counter unit (60) attached to a base end thereof. Further, the inhaler canister assembly (70) comprises first position ensuring means (110, 230), the actuator body comprises second position ensuring means (120,210), wherein the first and second position ensuring means being complementary mating means, and the first and second position ensuring means being so arranged that the inhaler device (10) cannot be fired, nor the counter unit (60) count unless the first and second position ensuring means are in a mating relationship. There is also provided an inhaler canister assembly (70) and an actuator body (20).
Inventor(s): Hodson; Darren (Leicestershire, GB), Treneman; William (Cambridgeshire, GB)
Assignee: AstraZeneca AB (Sodertaije, SE)
Application Number:11/571,645
Patent Claim Types:
see list of patent claims
Delivery; Device; Use; Use; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
AstrazenecaSYMBICORTbudesonide; formoterol fumarate dihydrateAEROSOL, METERED;INHALATION021929-001Jul 21, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
AstrazenecaSYMBICORTbudesonide; formoterol fumarate dihydrateAEROSOL, METERED;INHALATION021929-002Jul 21, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,528,545

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0401786Jul 05, 2004
Sweden0401786Jul 5, 2004
PCT Information
PCT FiledJune 23, 2005PCT Application Number:PCT/SE2005/000996
PCT Publication Date:January 12, 2006PCT Publication Number: WO2006/004498

International Patent Family for Patent: 8,528,545

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
BrazilPI0512973► Subscribe
BrazilPI0512999► Subscribe
Canada2570078► Subscribe
Canada2570131► Subscribe
China1976735► Subscribe
Hong Kong1101897► Subscribe
China101035582► Subscribe
China102058921► Subscribe
Cyprus1108679► Subscribe
Germany602005010434► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Citi
Accenture
McKesson
Novartis
Healthtrust
Merck
Medtronic
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot